Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List
Target: Interleukin-33; IL-33; Suppression of Tumorigenicity 2 (ST2) receptor; interleukin-1 receptor-like 1 (IL1RL1)
This report provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.
Interleukin-33 (IL-33) is an IL-1 family member, which exhibits both pro- and anti-inflammatory properties solely based on the type of the disease itself. Generally, IL-33 is expressed by both endothelial and epithelial cells and mediates its function based on the interaction with various receptors, mainly with the receptor Suppression of Tumorigenicity 2 (ST2) variants. IL-33 is a potent inducer for the Th2 immune response.
IL-33 initiates its signalling pathway by binding to the ST2 receptor, or also known as IL-1R4, with variants which are comprised of ST2L, sST2, ST2V, and ST2LV. Apart from ST2, the interaction of IL-33 with a single immunoglobulin IL-1R-related molecule (SIGIRR) has been documented as well. With exception from other IL-1 family members, IL-33 is primarily involved in the Th2 immune response induction.
Multiple studies have indicated IL-33 as a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 directly mediates release of disease-associated downstream cytokines, which recruit pro-inflammatory cells that mediate atopic disease.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
Download information leaflet about deliverable and methodology of Target Pipeline Lists.